

Michael Fraser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6847278/publications.pdf>

Version: 2024-02-01

30
papers

3,779
citations

394286

19
h-index

526166

27
g-index

32
all docs

32
docs citations

32
times ranked

6747
citing authors

#	ARTICLE	IF	CITATIONS
1	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1781.	5.8	32
2	Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer. <i>European Urology</i> , 2021, 79, 466-467.	0.9	0
3	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. <i>European Urology Focus</i> , 2021, 7, 513-521.	1.6	0
4	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. <i>Cancer Research</i> , 2021, 81, 5833-5848.	0.4	7
5	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. <i>Nature Communications</i> , 2021, 12, 6248.	5.8	15
6	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. <i>Journal of Biomedical Optics</i> , 2021, 26, .	1.4	4
7	The telomere length landscape of prostate cancer. <i>Nature Communications</i> , 2021, 12, 6893.	5.8	7
8	Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2020, , .	2.6	13
9	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy caseâ€“control study with multicohort validation. <i>PLoS Medicine</i> , 2020, 17, e1003281.	3.9	19
10	Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. <i>Nature Communications</i> , 2020, 11, 441.	5.8	51
11	Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1965-1976.	3.2	55
12	Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. <i>Cancer Cell</i> , 2019, 36, 674-689.e6.	7.7	52
13	Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 572-573.	0.9	0
14	The Proteogenomic Landscape of Curable Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 414-427.e6.	7.7	168
15	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , 2019, 176, 831-843.e22.	13.5	317
16	Molecular landmarks of tumor hypoxia across cancer types. <i>Nature Genetics</i> , 2019, 51, 308-318.	9.4	480
17	Prostate Cancer Genomic Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 87-110.	0.8	8
18	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	9.4	182

#	ARTICLE	IF	CITATIONS
19	The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. <i>Cell</i> , 2018, 173, 1003-1013.e15.	13.5	176
20	Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. <i>BMC Cancer</i> , 2018, 18, 8.	1.1	93
21	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017, 541, 359-364.	13.7	462
22	Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. <i>Nature Communications</i> , 2017, 8, 13671.	5.8	182
23	TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. <i>Nature Genetics</i> , 2017, 49, 1336-1345.	9.4	161
24	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
25	BAMQL: a query language for extracting reads from BAM files. <i>BMC Bioinformatics</i> , 2016, 17, 305.	1.2	20
26	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	9.4	395
27	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. <i>Nature Genetics</i> , 2015, 47, 367-372.	9.4	380
28	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2014, 15, 1521-1532.	5.1	291
29	ShatterProof: operational detection and quantification of chromothripsis. <i>BMC Bioinformatics</i> , 2014, 15, 78.	1.2	49
30	PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 1015-1027.	3.2	119